Granulation lines for research and development, takes the process from dispensed raw materials to finished tablet. Our systems clearly demonstrates the flexibility that can be achieved throughout the process – including high shear granulation, pelletizing and blending, etc.
All technologies can be brought together in an integrated process system that mimics the hundreds of large-scale plants provided by GEA globally. It epitomizes the approach of ensuring customers receive the same technology from the laboratory through to production, using the same containment and process technologies to ensure seamless scale-up and the most flexible blend of process capabilities.
Showing 4 of 8
Committed to providing flexible, modular equipment to support research and development in the pharmaceutical industry, the multipurpose AirConnect from GEA delivers a range of fluid bed processing solutions for small-scale applications.
The ConsiGma® 1 offers standalone continuous twin-screw granulation and drying for small-scale R&D operations. It allows users to develop the process and achieve high granule quality on a compact unit.
The ConsiGma® CF20 test rig is a standalone module that allows you to characterize the feeding behavior of your products during the early stages of R&D.
An indispensable part of the ConsiGma portfolio, the Conductor control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line
The impact of global warming is increasingly apparent all over the world. Towns and cities everywhere face the same challenge: providing their communities with reliable, affordable, sustainably sourced heat. GEA spoke with an expert in the field, Kenneth Hoffmann, Manager, Heat Pumps at GEA Heating & Refrigeration Technologies, about tackling global warming faster.
Something caught Farmer Tom's eye. Instead of another product demo, GEA showcased innovations via AR. That's only the start of GEA's interactive digital farm.
GEA scientists are working with researchers at the Graz University of Technology to configure a homogenization process and technology that turns eucalyptus pulp into 3D-printed, organic structures mimicking human veins, arteries and other tissues.